Published on 21/01/2026
ALT transition technical lead Bruno Gatimel says 18 of these trials will also contribute to work already underway to identify alternatives for organophosphates and synthetic pyrethroids which are being phased out, and Group 3 and Group 7 fungicides, which are strongly susceptible to resistance.
Products from 17 crop protection companies are included in the trials, and the products being evaluated include biologicals, innovative synthetic products and physical modes of action.
In addition to 14 trials previously approved in 10 crops for this season, a further eight trials in four crops have now been given the green light.
The crops involved are process peas and pea seed, for control of Aschochyta blight, and squash, for control of aphids, armyworm and earworms.
Bruno Gatimel says these trials will all evaluate efficacy of novel insecticides and softer biological options, which are essential to support sustainable pest control strategies.
Residue testing will also be undertaken in the squash work to develop residue decay curves for the synthetic chemical options trialled.
Data gathered through efficacy and residue trials supports access to innovative crop protection products for growers and their industry.
For products to achieve registration or a new label claim through the regulatory process, robust data and multiple sets of data are required, including several seasons of local trial results.
Getting information about product efficacy and performance also supports improved management of pesticide resistance in the longer term by providing growers with a broader range of crop protection options, Gatimel says.
The ALT team considers several factors when it comes to sharing the results from trials, and works closely with product owners and registrants to define what information can be shared, using anonymised or aggregated data to protect intellectual property.
Many of the products involved in this season’s trials show broad potential across pests, diseases, and crops, meaning insights from one specific trial can still offer valuable benefits to other sectors and the wider industry.